Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Vistagen Therapeutics Inc    VTGN

VISTAGEN THERAPEUTICS INC

(VTGN)
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

VISTAGEN THERAPEUTICS, INC. : Regulation FD Disclosure (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/11/2019 | 05:38pm EDT

Item 7.01 Regulation FD Disclosure.

On January 7, 2019, VistaGen Therapeutics, Inc. (the "Company") began utilizing a new corporate presentation. A copy of the Corporate Presentation is attached hereto as Exhibit 99.1.

The information in this Item 7.01 of this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall Exhibit 99.1 filed herewith be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

In addition, this Current Report on Form 8-K and the exhibit(s) attached hereto may contain, among other things, certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, (i) statements with respect to the Company's plans, objectives, expectations and intentions; and (ii) other statements identified by words such as "may", "could", "would", "should", "believes", "expects", "anticipates", "estimates", "intends", "plans" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties.

Item 9.01 Exhibits.

See Exhibit Index.

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VISTAGEN THERAPEUTICS INC
06/25VISTAGEN THERAPEUTICS : Management's Discussion and Analysis of Financial Condit..
AQ
06/21VISTAGEN THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Contin..
AQ
06/21VISTAGEN THERAPEUTICS : Announces Positive Preclinical Data Supporting AV-101's ..
AQ
05/31VISTAGEN THERAPEUTICS : Announces Positive Preclinical Data Supporting AV-101's ..
AQ
05/08VISTAGEN THERAPEUTICS : to Present at ChinaBio Partnering Forum in Shanghai, Chi..
AQ
05/02VISTAGEN THERAPEUTICS, INC. : Regulation FD Disclosure, Other Events, Financial ..
AQ
04/04VISTAGEN THERAPEUTICS, INC. : Other Events (form 8-K)
AQ
04/02VISTAGEN THERAPEUTICS : Positive Pilot Phase 3 Data Position VistaGen's PH94B Ne..
AQ
03/14VISTAGEN THERAPEUTICS, INC. : Regulation FD Disclosure, Other Events (form 8-K)
AQ
03/04VISTAGEN THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Financ..
AQ
More news
Financials (USD)
Sales 2020 -
EBIT 2020 -19,6 M
Net income 2020 -19,6 M
Debt 2020 -
Yield 2020 -
P/E ratio 2020 -1,78x
P/E ratio 2021 -2,35x
Capi. / Sales2020 infx
Capi. / Sales2021 infx
Capitalization 28,1 M
Chart VISTAGEN THERAPEUTICS INC
Duration : Period :
Vistagen Therapeutics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VISTAGEN THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 4,00  $
Last Close Price 0,66  $
Spread / Highest target 507%
Spread / Average Target 507%
Spread / Lowest Target 507%
EPS Revisions
Managers
NameTitle
Shawn K. Singh Chief Executive Officer & Director
H. Ralph Snodgrass President, Director & Chief Scientific Officer
Jon Sheldon Saxe Chairman
Jerrold D. Dotson Chief Financial Officer, Secretary & VP
Mark A. Smith Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
VISTAGEN THERAPEUTICS INC-55.33%29
CSL LIMITED19.36%70 128
BIOGEN-23.10%44 906
ALEXION PHARMACEUTICALS24.10%27 243
GRIFOLS19.96%18 793
SAMSUNG BIOLOGICS CO LTD--.--%16 989